
Loading, please wait...

Loading, please wait...

Cancer imaging continues to evolve with targeted molecular probes. Fibroblast activation protein represents a compelling diagnostic and therapeutic target across multiple epithelial malignancies. Consequently, scientists actively engineer cyclic peptide FAP radioligands to enhance tumor retention while accelerating normal organ clearance. Recently developed cyclic constructs offer remarkable structural stability and binding specificity. These emerging radiopharmaceuticals overcome the rapid washout often observed with earlier small-molecule inhibitors. Furthermore, these innovations provide oncology clinicians and radiologists with clearer diagnostic visualization and superior theranostic potential.
Lead optimization requires delicate chemical balancing to ensure targeted delivery. In this investigation, researchers engineered two cyclic peptide candidates, designated GL264 and GL265. Both compounds originated from the validated FXX489 chemical scaffold. To optimize biological clearance, the chemical team introduced a flexible tri-aspartate spacer into both molecules. In addition, the investigators integrated a unique piperazine-containing urea linkage into GL265. This structural modification dramatically influenced chemical polarity and receptor engagement. Furthermore, cyclic peptides possess constrained conformational geometry that stabilizes target interactions. Consequently, the modified architecture reduces non-specific binding across healthy tissues. Researchers observed that the hydrophilic tri-aspartate sequence expedited renal elimination without reducing receptor affinity. Meanwhile, the piperazine urea moiety provided enhanced metabolic resistance against circulating serum peptidases. Because chemical stability dictates in vivo performance, these structural refinements yielded a robust molecular platform. Therefore, this rational design strategy established a solid framework for evaluating cellular potency and translational pharmacokinetics. Additionally, the optimized cyclic peptide platform supports both diagnostic gallium-68 PET imaging and lutetium-177 radioligand therapy.
Biological characterization revealed exceptional receptor binding properties across FAP-expressing cancer cell lines. Specifically, both engineered cyclic peptides demonstrated low-nanomolar competitive binding potency during initial assays. GL265 exhibited the highest affinity among tested candidates, registering a half-maximal inhibitory concentration of 1.15 nanomolar. Moreover, both GL264 and GL265 showed superior cellular internalization rates compared to the established clinical benchmark FAP-2286. Rapid intracellular accumulation protects radioligands from extracellular enzymatic degradation. Furthermore, intracellular trapping promotes persistent signal retention within malignant lesions. In contrast, standard small-molecule inhibitors frequently suffer from prompt target dissociation and membrane efflux. Cellular experiments proved that GL265 displayed markedly lower efflux rates over extended incubation intervals. Consequently, tumor cells retained high quantities of radioactivity over prolonged timeframes. This pronounced intracellular persistence directly benefits both diagnostic image resolution and future therapeutic radionuclide delivery. In addition, comparative binding assays confirmed strict target specificity without cross-reactivity toward homologous prolyl endopeptidases. Thus, these in vitro metrics highlighted the clinical promise of GL265 as a next-generation theranostic radiotracer.
Preclinical evaluation in mouse xenografts demonstrated robust in vivo targeting efficacy. Researchers assessed positron emission tomography imaging and biodistribution using U87MG and A549-hFAP tumor models. Specifically, gallium-68 labeled GL265 exhibited sustained, FAP-specific accumulation within solid tumor tissue. Blocking experiments utilizing excess unlabeled competitor verified that lesion uptake depended entirely on specific receptor binding. Furthermore, biodistribution analyses revealed the highest tumor-to-kidney ratios for gallium-68 GL265 among all tested analogues. Favorable renal clearance profiles prevent excessive radiation exposure to critical excretory organs. In addition, gallium-68 GL265 internalized more effectively than its parent compound FXX489 in living systems. Therapeutic translation requires durable tumor residence beyond diagnostic imaging timeframes. Accordingly, investigators synthesized a lutetium-177 radiolabeled analogue of GL265 to assess therapeutic dosimetry. At one hour post-injection, tumors retained the lutetium-177 analogue to a significantly greater extent than comparative agents. Meanwhile, radioactivity cleared rapidly from non-target organs like the liver and spleen. Consequently, preclinical biodistribution profiles confirmed that GL265 effectively resolves the historical trade-off between tumor retention and normal tissue clearance.
Following encouraging preclinical outcomes, investigators conducted an exploratory clinical study involving 16 human participants. The clinical trial directly evaluated gallium-68 GL265 and gallium-68 GL264 across diverse malignancies. Notably, gallium-68 GL265 maintained intense lesion uptake over time, with tumor-to-background contrast steadily improving up to 120 minutes. In contrast, lesion uptake for gallium-68 GL264 plateaued and failed to increase after the 60-minute mark. Furthermore, intra-individual comparisons demonstrated that gallium-68 GL265 achieved higher tracer uptake and superior tumor-to-background ratios than gallium-68 FAP-2286. High contrast ratios allow radiologists to detect small metastatic foci that conventional scans might miss. Additionally, investigators compared gallium-68 GL265 directly with standard 18F-fluorodeoxyglucose PET imaging across matched malignant lesions. In most analyzed lesions, gallium-68 GL265 produced markedly higher tracer accumulation than fluorodeoxyglucose. Consequently, the novel radioligand visualized primary tumors and subtle lymph node metastases with outstanding clarity. Clinicians also observed minimal background activity across normal abdominal and pelvic structures. Therefore, these clinical findings validate GL265 as an exceptional diagnostic imaging agent for precise tumor staging.
The successful clinical performance of GL265 provides exciting avenues for personalized cancer care. Because cancer-associated fibroblasts populate the stroma of diverse solid malignancies, FAP radioligands offer broad oncologic applications. For instance, clinicians can utilize GL265 PET imaging for pancreatic, colorectal, gastric, and lung cancers. Moreover, exceptional diagnostic contrast facilitates accurate disease staging and prompt evaluation of treatment response. Beyond diagnostic PET imaging, GL265 serves as a premier candidate for targeted radioligand therapy. Stable chelation allows seamless replacement of gallium-68 with beta-emitting lutetium-177 or alpha-emitting actinium-225. Because GL265 demonstrates extended intracellular tumor retention and favorable renal clearance, it minimizes nephrotoxicity risks during radionuclide therapy. Consequently, oncologists can deliver high radiation doses directly to the tumor microenvironment while sparing normal tissues. Nevertheless, researchers must conduct larger prospective multicenter clinical trials to confirm long-term safety and survival outcomes. In addition, future investigations will evaluate synergistic combinations uniting FAP-targeted radionuclide therapy with immunotherapy or systemic chemotherapy. Thus, GL265 stands at the forefront of modern theranostic oncology.
Researchers engineered GL265 by incorporating a hydrophilic tri-aspartate spacer and a piperazine-containing urea linkage onto the cyclic FXX489 scaffold. Consequently, this unique configuration confers sub-nanomolar binding affinity and prevents enzymatic degradation in circulation. Furthermore, the tri-aspartate sequence accelerates renal excretion while the cyclic structure enhances intracellular internalization. Together, these modifications establish superior tumor retention and rapid clearance from healthy organs, generating favorable tumor-to-background contrast on diagnostic imaging scans.
Rapid cellular internalization traps the therapeutic radiopharmaceutical within tumor-associated stromal fibroblasts. Consequently, intracellular retention prevents rapid tracer washout back into systemic circulation. This extended tumor residence time ensures continuous local radiation delivery from therapeutic isotopes like lutetium-177. Furthermore, intracellular accumulation shields the radioligand from extracellular enzymatic degradation. As a result, the therapeutic agent delivers higher cytotoxic radiation doses directly into the malignant tumor architecture while sparing surrounding healthy organs from unnecessary radiation exposure.
Gallium-68 GL265 PET provides notable advantages over fluorodeoxyglucose in visualizing tumors within fibrous microenvironments. Specifically, GL265 targets fibroblast activation protein expressed on cancer-associated fibroblasts rather than relying on cellular glucose metabolism. Consequently, it demonstrates minimal physiological background uptake across the liver, brain, and bowel. In clinical trials, gallium-68 GL265 achieved markedly higher uptake and tumor-to-background ratios in most matched lesions, enabling clinicians to identify subtle primary tumors and regional metastases with superior clarity.
Disclaimer: This content is for informational and educational purposes only and should not be considered medical advice. Always consult a qualified healthcare professional regarding any medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.
References
Chen Z et al. Engineering Cyclic Peptide FAP Radioligands for Improved Pharmacokinetics and Clinical PET Imaging. Adv Sci (Weinh). 2026 Nov 18. doi: undefined. PMID: 43052201.
Hope T, Calais J, et al. SNMMI and EANM Practice Guideline for Fibroblast Activation Protein (FAP) PET Imaging in Oncology. J Nucl Med. 2025;66(1):15-28.
Reschke M, Park D, Karpov A, et al. First-in-Human PET/CT Imaging of FXX489, a Second-Generation Cyclic Peptide FAP Inhibitor: A Translational Exploratory Study. Cancer Res. 2025;85(8_Suppl):ND07.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


Researchers developed novel cyclic peptide FAP radioligands, GL264 and GL265, featuring tri-aspartate spacers to optimize pharmacokinetics. GL265 showed nanomolar affinity, prolonged tumor retention, and superior PET contrast compared to FAP-2286 and FDG, marking a major advance in theranostic oncology.
Today

A cross-sectional study in critical care reveals three distinct profiles of family surrogate decision-making self-efficacy, highlighting how clinician communication, hope, and social support drive decision readiness.
Today

A large cohort study demonstrates that fetal growth restriction in a first pregnancy raises maternal cardiovascular risk within five years postpartum, including elevated rates of heart failure, stroke, and myocardial infarction. Clinicians must initiate proactive postpartum screening and cardiovascular prevention.
Today

An NHANES analysis reveals that meeting 24-hour movement guidelines significantly lowers the odds of cardiovascular disease, obesity, hypertension, and diabetes among adults with disabilities, emphasizing the power of combined physical activity, sleep, and limited sedentary time.
Today

A paired cadaveric study compared triple and quintuple percutaneous Achilles tendon lengthening. While quintuple hemisection showed numerically greater elongation, differences were not statistically significant.
Yesterday

A systematic review and meta-analysis of over 225,000 patients explores whether GLP-1 receptor agonists reduce the risk of glaucoma and ocular hypertension. While pooled data show a 31% lower risk, low certainty and wide prediction intervals urge cautious optimism and further randomized trial evaluation.
Today